Evidence map›Paper›PMID 40459634›Full record

ArticleFunctional & integrative genomics2025

A novel oncogene, leucine-rich repeat protein 1, mediates hypoxia-induced hepatocellular carcinoma progression.

Li Tao, Yixian Guo, Runkun Liu, Meng Lv, Yufeng Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Functional & integrative genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Li Tao *Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China.
Yixian Guo *Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China.
Runkun LiuDepartment of Hepatobiliary Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China.
Meng LvDepartment of Hepatobiliary Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China.
Yufeng WangDepartment of Hepatobiliary Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China. wangyufeng@stu.xjtu.edu.cn.

Funding

Fundamental Research Funds for the Central Universities xzy012022093National Natural Science Foundation of China 82103565National Training Program of Innovation and Entrepreneurship for Undergraduates S202310698660
6 · The paper itself

Abstract

The involvement of leucine rich repeats protein 1 (LRR1) in various biological processes has been established, but its specific role and potential mechanisms in hepatocellular carcinoma (HCC) remain unclear. The aim of this study was to explore the potential expression, function, and mechanisms of LRR1 in HCC. Data acquired from TCGA, GEO and other online databases was used to investigate the expression and roles of LRR1 in HCC through various approaches, including expression profiling, clinical significance analysis, methylation status examination, immune infiltration assessment, genomic mutation analysis, and pathway network exploration. With findings in bioinformatic analysis, we further validated the involvement of LRR1 in HCC progression by cellular experiments. The expression of LRR1 is significantly upregulated in HCC compared to normal liver tissues and cell line. Additionally, the involvement of LRR1 was implicated in various modifications across diverse aspects associated with HCC. Enrichment analysis indicated that LRR1 was induced by hypoxia in HIF-1-dependent manner. The cell experiments convincingly demonstrated the pivotal role of LRR1 in tumor cell proliferation, migration, invasion and angiogenesis under the regulation of HIF-1. Our findings demonstrate a novel oncogene LRR1 in HCC, which is also a HIF-1 target gene and functions as a promising biomarker and contributes to the hypoxia-induced progression of HCC through a HIF-1/LRR1 manner.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsCell Line, TumorCell MovementCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHumansHypoxia-Inducible Factor 1, alpha SubunitHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitBioinformaticsHepatocellular carcinomaHIF-1HypoxiaLRR1

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.